Amneal (NYSE: AMRX) Co-CEO receives major performance-based RSU award
Amneal Pharmaceuticals' Co-CEO, Chintu Patel, has been granted 544,663 performance-based restricted stock units (RSUs). These RSUs are tied to the company's Class A common stock performance over a three-year period, with vesting contingent on achieving specific average closing price targets. The actual number of shares received can range from 0% to 200% of the target, with full vesting scheduled for February 28, 2029, if conditions are met.
[Form 4/A] Amneal Pharmaceuticals, Inc. Amended Insider Trading Activity
Amneal Pharmaceuticals President & Co-CEO Chirag K. Patel has received a grant of 544,663 performance-based restricted stock units (RSUs) tied to Class A common stock. These RSUs are a compensation award that could convert into shares based on the company's stock performance over a three-year period. The number of shares ultimately received can range from 0% to 200% of the target, with full vesting on February 28, 2029, if earned.
Major holder Dipan Patel cuts Amneal Pharmaceuticals (AMRX) stake to 5.4%
Dipan Patel has reduced his beneficial ownership in Amneal Pharmaceuticals Inc. (AMRX) to 5.4% of Class A common stock, down from a previous holding. Through trusts he controls, Patel sold 6,924,729 shares in open market transactions between November 14, 2024, and December 31, 2025, at prices ranging from $7.74 to $12.42 per share. Following these sales, he retains sole voting and dispositive power over 16,904,263 shares.
How Amneal’s Margin-Focused 2026 Outlook and 2025 Results Could Impact Amneal Pharmaceuticals (AMRX) Investors
Amneal Pharmaceuticals (AMRX) reported 2025 revenues of US$3.02 billion and operating income of US$421 million, along with a 3.5x net leverage. Their 2026 guidance emphasizes modest revenue growth but faster adjusted EBITDA and EPS growth, driven by higher-margin products like biosimilars and new launches. This strategy aims to offset pricing pressure in generics and reshape investor perception towards margin-focused growth.
A Look At Amneal Pharmaceuticals (AMRX) Valuation After Strong 2025 Results And 2026 Growth Guidance
Amneal Pharmaceuticals (AMRX) reported strong 2025 results with US$3.02 billion in revenue and US$421 million in operating income, and projected growth in adjusted EBITDA and EPS for 2026. Despite a recent share price pullback, the stock has shown significant long-term returns. Analysts suggest the stock is undervalued, estimating a fair value of $16.80 against a current price of $12.39, although its high P/E ratio compared to the industry indicates potential valuation risk.
What Amneal Pharmaceuticals (AMRX)'s Return to Profitability and 2026 Guidance Means For Shareholders
Amneal Pharmaceuticals reported strong fourth-quarter and full-year 2025 results, returning to profitability with net income of US$72.06 million and issuing optimistic 2026 net revenue guidance of US$3.05 billion to US$3.15 billion. The company's strategy involves a mix of generics, biosimilars, and specialty drugs, with future growth dependent on product launches, while managing high leverage remains a key risk for investors. Analysts project continued revenue and earnings growth, leading to a potential fair value upside for the stock.
Amneal (AMRX) EVP nets stock from RSU vesting and tax withholdings
Amneal Pharmaceuticals EVP Nikita Shah reported the vesting of restricted stock units (RSUs) and performance-based units, along with the disposition of shares to cover tax withholding obligations. Performance-based RSUs granted in 2023 vested at 200% of the targeted number due to the company's Class A stock performance. These transactions, detailed in a Form 4 SEC filing, reflect equity compensation rather than discretionary open market sales.
Amneal (AMRX) CFO earns 458,716 performance RSUs, with shares withheld for taxes
Amneal Pharmaceuticals' CFO, Tasos Konidaris, reported the vesting of multiple equity awards, including restricted stock units and performance-based restricted stock units. A significant grant of 458,716 performance-based RSUs vested at 200% of the target amount due to share-price conditions being met. Portions of the newly issued shares were withheld to cover tax obligations, rather than being sold in the open market, and Konidaris now directly holds 449,434 shares of Class A Common Stock.
AMRX SEC Filings - Amneal Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Amneal Pharmaceuticals (AMRX) SEC filings, including 10-K, 10-Q, and 8-K reports, designed for investors and traders. It highlights recent insider trading activities and sales by executives, detailing share disposals, option exercises, and proposed sales with specific dates and values. The platform also offers AI-powered tools to help users interpret these regulatory documents more efficiently.
Amneal (AMRX) Co-CEO gains shares via RSU and performance awards
Amneal Pharmaceuticals, Inc. (AMRX) Co-CEO Chirag K. Patel received Class A Common shares from the vesting of performance-based restricted stock units and additional restricted stock units. To cover tax withholding obligations, he disposed of a portion of these shares. Following these transactions, Patel's direct holdings include over 1.39 million Class A Common Stock shares and 185,185 restricted stock units, with an additional 21.2 million Class A shares held indirectly through family trusts.
Amneal (NYSE: AMRX) EVP Boyer settles RSUs, withholds stock for tax
Amneal Pharmaceuticals Executive Vice President Andrew S. Boyer recently settled various Restricted Stock Units (RSUs), including performance-based and time-based grants. These RSUs vested and were converted into Amneal Class A Common Stock. To cover tax obligations related to these vestings, Boyer had a portion of the shares withheld, with specific amounts at $13.31 and $13.30 per share. Following these transactions, Boyer directly holds 426,072 shares of Amneal Class A Common Stock.
Amneal (NYSE: AMRX) EVP Andrew Boyer granted time- and performance-based RSUs
Amneal Pharmaceuticals Executive Vice President Andrew S. Boyer has been granted 65,359 restricted stock units (RSUs) and 65,359 performance-based restricted stock units. The time-based RSUs will vest in four equal annual installments starting March 2, 2027, while the performance-based units are tied to average closing price targets of the company's Class A common stock over a three-year period ending February 28, 2029, with a potential payout from 0% to 200% of the target. This insider transaction was reported in a Form 4 SEC filing, indicating it as equity compensation rather than a cash purchase.
Amneal (NYSE: AMRX) CFO granted time- and performance-based RSUs
Amneal Pharmaceuticals' Executive Vice President & CFO, Tasos Konidaris, was granted 72,622 time-based Restricted Stock Units (RSUs) and 72,622 performance-based RSUs. The time-based units begin vesting in four equal annual installments starting March 2, 2027, while the performance-based units are tied to the company's average closing share price over a three-year period and can vest from 0% to 200% of the target, with full vesting on February 28, 2029, if conditions are met. This information was reported in a Form 4 SEC filing.
Amneal (NYSE: AMRX) grants RSU and performance stock awards to EVP
Amneal Pharmaceuticals (NYSE: AMRX) has granted its EVP and Chief Legal Officer, Jason B. Daly, two equity awards: 65,359 restricted stock units (RSUs) and 65,359 performance-based restricted stock units. The RSUs will vest in four equal annual installments starting March 2, 2027, while the performance-based units, tied to three-year stock price targets, will vest on February 28, 2029, with potential payouts ranging from 0% to 200% of the target.
Amneal (AMRX) Co-CEO awarded time- and performance-based RSUs
Amneal Pharmaceuticals President and Co-CEO Chirag K. Patel was granted 190,632 time-based restricted stock units (RSUs) and 354,031 performance-based RSUs, as reported in a Form 4 SEC filing. The time-based units vest in four equal annual installments starting March 2, 2027, while the performance-based units are tied to the company's average closing share price over a three-year period, with potential vesting from 0% to 200% of the target by February 28, 2029. This award signifies equity compensation valued at $0 per unit, with the ultimate value depending on future vesting and Amneal's share price.
Amneal (NYSE: AMRX) EVP awarded time- and performance-based RSUs
Amneal Pharmaceuticals Executive Vice President Nikita Shah has been granted 65,359 time-based restricted stock units and 65,359 performance-based restricted stock units. The time-based units will vest in four equal annual installments starting March 2, 2027, while the performance-based units are tied to stock price targets over a three-year period, vesting on February 28, 2029, with a potential payout from 0% to 200%. This Form 4 filing details the equity awards as part of her compensation.
Amneal (AMRX) Co-CEO Chintu Patel gets major RSU and PSU grants
Amneal Pharmaceuticals Co-CEO Chintu Patel received significant equity awards, including 190,632 restricted stock units (RSUs) vesting over four years and 354,031 performance-based restricted stock units (PSUs). The PSUs are tied to the company's stock price performance over a three-year period, with a potential payout ranging from 0% to 200% of the target shares. These grants align Patel's compensation with Amneal's long-term stock performance and continued service.
The Bull Case For Amneal Pharmaceuticals (AMRX) Could Change Following New 2026 Revenue Guidance Release
Amneal Pharmaceuticals recently released its 2026 revenue guidance, projecting net revenue between US$3.05 billion and US$3.15 billion. This new guidance clarifies management's expectations for the company's growth across generics, injectables, biosimilars, and specialty products. While supporting Amneal's diversification strategy, investors are encouraged to consider this outlook alongside ongoing pricing pressures, regulatory risks, and the recent nationwide opioids settlement.
Amneal Q4 2025 Highlights Shift Toward Higher Value Pharma Segments
Amneal Pharmaceuticals (NasdaqGS:AMRX) reported strong Q4 2025 results, demonstrating a strategic shift towards higher-value segments like specialty, injectables, biosimilars, and complex generics. The company announced multiple product launches, regulatory approvals, and highlighted a promising pipeline, including a collaboration with Pfizer on GLP-1 therapies. Analysts see the stock as undervalued, trading about 19% below the consensus target, while Simply Wall St's model estimates it is significantly below its fair value.
Earnings Scheduled For February 27, 2026
This article lists companies scheduled to report earnings on February 27, 2026, including their estimated earnings per share and revenue. It details both companies reporting before and after the market bell, providing financial projections from Benzinga's automated content engine.
Amneal Pharmaceuticals (AMRX) Return To Profit Tests High 60.3x P/E Narrative
Amneal Pharmaceuticals (AMRX) recently returned to profitability, reporting FY 2025 Q4 revenue of US$814.3 million and basic EPS of US$0.11, with trailing twelve-month revenue at US$3.0 billion and EPS of US$0.23. Despite this P/E of 60.3x and weak interest coverage raise concerns among investors, especially given the forecasted 4.9% annual revenue growth, which is below the broader market's 10.3% benchmark. The article highlights both bullish arguments, such as diversification into branded products, and bearish concerns regarding the high valuation and debt burden.
Amneal Pharmaceuticals Q4 Earnings Summary & Key Takeaways
Amneal Pharmaceuticals (NASDAQ: AMRX) released its Q4 earnings report, beating estimated earnings by 16.67% with an EPS of $0.21 against an estimate of $0.18. Revenue increased by $83.80 million year-over-year. The company also provided guidance for FY 2026, forecasting earnings between $0.93 and $1.03 per share.
Amneal (NASDAQ: AMRX) returns to profit and guides 2026 growth
Amneal Pharmaceuticals (NASDAQ: AMRX) reported a strong return to profitability in 2025 with net revenue of $3.02 billion and GAAP net income of $72 million. The company's adjusted EBITDA increased by 10% to $688 million, and adjusted diluted EPS rose to $0.83. Amneal also provided optimistic guidance for 2026, projecting net revenue between $3.05 billion and $3.15 billion, adjusted EBITDA of $720-$760 million, and adjusted diluted EPS of $0.93-$1.03, signaling continued growth and deleveraging.
Drugmaker Amneal swings from loss to $72M profit as sales hit $3B
Amneal Pharmaceuticals (Nasdaq: AMRX) reported strong Q4 and full-year 2025 financial results, achieving a net income of $72 million for the full year compared to a loss in 2024, with total net revenue reaching $3.02 billion. The company provided optimistic 2026 financial guidance, projecting net revenue between $3.05 billion and $3.15 billion and adjusted EBITDA of $720 million to $760 million, driven by growth in its Specialty and AvKARE segments and a robust pipeline of new product approvals. Investors reacted negatively on the day of the news, with AMRX declining 4.69%, despite the positive earnings report and future outlook.
Amneal Reports Fourth Quarter and Full Year 2025 Financial Results
Amneal Pharmaceuticals announced strong fourth quarter and full-year 2025 financial results, meeting or exceeding all guidance metrics. The company reported significant increases in net revenue and adjusted diluted EPS, driven by growth in its Specialty and AvKARE segments. Amneal also provided positive financial guidance for 2026, anticipating continued growth in net revenue and Adjusted EBITDA.
Assessing Amneal Pharmaceuticals (AMRX) Valuation After Recent Trading Momentum And Modest Undervaluation Estimate
Amneal Pharmaceuticals (AMRX) is currently assessed as modestly undervalued, trading at $14.58 against a fair value of $15.20. The company shows positive long-term momentum, driven by its diversification into branded and complex products and a robust pipeline, positioning it to benefit from global health trends. However, intense price pressure in U.S. generics and its debt load present potential challenges to this positive outlook.
Earnings Outlook For Amneal Pharmaceuticals
Amneal Pharmaceuticals (NASDAQ: AMRX) is set to release its quarterly earnings report on Friday, 2026-02-27, with analysts expecting an EPS of $0.18. The company has a history of beating EPS estimates, often followed by an increase in share price. Investors will be watching for the actual EPS and future guidance, as the stock has seen a 68.17% increase over the past 52 weeks.
Generic Drugs Focused Amneal Pharmaceuticals Revenue Crosses $800 Million
Amneal Pharmaceuticals reported a strong fourth quarter, with revenue increasing 11% year-over-year to $814.32 million and adjusted earnings of 21 cents, both beating analyst expectations. The company also provided its fiscal 2026 guidance, expecting adjusted earnings between 93 cents and $1.03, and sales of $3.05-$3.15 billion. Technical analysis shows mixed signals, with short-term weakness but a generally positive long-term trend, and analysts have a "Buy" rating on the stock.
Does S&P SmallCap 600 Entry And Parkinson’s Deal Reshape The Bull Case For Amneal Pharmaceuticals (AMRX)?
Amneal Pharmaceuticals (AMRX) has been added to the S&P SmallCap 600 Index and entered a research collaboration for a Parkinson's disease treatment. These developments aim to broaden its investor base and expand its neuroscience pipeline. While offering long-term potential, the company still faces challenges including pricing pressure in U.S. generics, high debt, and opioid settlement obligations, though analysts project significant revenue and earnings growth by 2028.
Amneal Pharmaceuticals stock hits 52-week high at 15.08 USD
Amneal Pharmaceuticals (AMRX) stock reached a new 52-week high of $15.08, reflecting substantial growth with a 92.55% increase over the past year and 56.83% in six months. Despite an InvestingPro analysis suggesting overvaluation with a high P/E ratio, analysts maintain a bullish outlook with price targets up to $18. Recent positive developments include FDA approvals for two denosumab biosimilars and an epinephrine injection, a partnership for a Parkinson's disease treatment, and inclusion in the S&P Dow Jones Indices.
Amneal Pharmaceuticals stock hits 52-week high at 15.08 USD By Investing.com
Amneal Pharmaceuticals' stock reached a 52-week high of $15.08, reflecting a 92.55% increase over the past year and a 56.83% gain in six months. Despite its strong performance, InvestingPro analysis suggests the stock might be overvalued, although analysts maintain a bullish outlook with price targets up to $18. Recent developments, including new FDA approvals and an upcoming inclusion in the S&P Dow Jones Indices, contribute to investor confidence and the company's growth potential.
Amneal Pharmaceuticals (AMRX) Valuation After Opioid Settlement Finalization And S&P Index Additions
Amneal Pharmaceuticals (AMRX) stock is reacting to two major developments: the finalization of a nationwide opioid settlement and its inclusion in several S&P indices. While the company's valuation is currently tight around analyst targets, a discounted cash flow model suggests a significant undervaluation. The article encourages investors to analyze their own assumptions regarding its future growth and profitability drivers.
How Investors Are Reacting To Amneal Pharmaceuticals (AMRX) Index Additions And Opioid Settlement Resolution
Amneal Pharmaceuticals faced an investment narrative shift with its inclusion in several S&P indices and the finalization of a nationwide opioid settlement. These developments are expected to increase investor visibility and reduce legal overhang. The focus for investors is now on the company's operating performance, cash generation, and balance sheet resilience, rather than potential litigation surprises.
If You Invested $100 In Amneal Pharmaceuticals Stock 5 Years Ago, You Would Have This Much Today
This article analyzes the performance of Amneal Pharmaceuticals (NASDAQ: AMRX) stock over the past five years. An investment of $100 five years ago would be worth $276.92 today, reflecting an average annual return of 22.74%. The article highlights the significant impact of compounded returns on investment growth.
Is It Too Late To Consider Amneal Pharmaceuticals (AMRX) After Its Strong Multi Year Run?
Amneal Pharmaceuticals (AMRX) has experienced significant stock growth over several years, leading investors to question its current valuation. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 79.8%, with an intrinsic value of US$69.18 per share compared to its recent price of US$13.95. Additionally, its Price/Sales (P/S) ratio of 1.49x is below both the industry average and Simply Wall St's fair ratio of 2.99x, further indicating undervaluation.
Amneal Pharmaceuticals, Inc. Added to S&P SmallCap 600® Index
Amneal Pharmaceuticals, Inc. has been added to the S&P SmallCap 600® Index, effective January 30, 2026, a move that analysts believe reflects the company's consistent financial performance and increased visibility among investors. This inclusion is expected to enhance trading liquidity and broaden Amneal's investor base, recognizing its position as a global biopharmaceutical company focusing on a diverse portfolio of products. The company's executives expressed satisfaction with this recognition, highlighting its strategic importance for growth and investor awareness.
Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026
Amneal Pharmaceuticals, Inc. announced it will release its fourth quarter and full year 2025 financial results on Friday, February 27, 2026, before market open. The company will host an audio webcast at 8:30 a.m. ET, accessible through its Investor Relations website. Amneal, a global biopharmaceutical company, focuses on affordable medicines, specialty pharmaceuticals, and distribution for the U.S. federal government and other markets.
Assessing Amneal Pharmaceuticals (AMRX) Valuation After Recent Share Price Momentum
Amneal Pharmaceuticals (AMRX) has experienced notable share price momentum but a recent pullback. The stock appears undervalued based on a 1.4x Price to Sales ratio compared to peers and an estimated fair range, and a Discounted Cash Flow model suggests a significantly higher fair value of US$69.18 per share. Investors are encouraged to consider these valuation indicators alongside potential risks like slowing revenue growth or continued margin pressure in the competitive generics market.
Amneal Pharmaceuticals stock hits 52-week high at $13.48 By Investing.com
Amneal Pharmaceuticals (AMRX) stock reached a 52-week high of $13.48, reflecting strong market performance with a 62.35% total return over the past year. The company, with a market capitalization of $4.2 billion, has a "GREAT" financial health score and expects profitability this year. Recent FDA approvals for biosimilars and an epinephrine injection, along with a research collaboration for Parkinson's disease treatment, further highlight its growth and expansion.
Amneal Pharmaceuticals stock hits 52-week high at $13.48 By Investing.com
Amneal Pharmaceuticals (AMRX) stock recently hit a 52-week high of $13.48, reflecting a significant market performance with a 62.35% total return over the past year. The company boasts a market capitalization of $4.2 billion and strong financial health. Recent achievements include FDA approval for two denosumab biosimilars (Boncresa and Oziltus) and an epinephrine injection, alongside a research collaboration with KeifeRx for a Parkinson's disease treatment.
Amneal Pharmaceuticals stock hits 52-week high at $13.04
Amneal Pharmaceuticals (AMRX) stock recently hit a 52-week high of $13.04, reflecting a 63.58% rise over the past year and a 50.95% gain in six months. This surge is attributed to strategic initiatives, favorable market conditions, and strong investor confidence highlighted by a bullish analyst consensus. The company recently received FDA approvals for two denosumab biosimilars and an epinephrine injection, and reported positive interim results for its Parkinson’s disease treatment, CREXONT.
A Look At Amneal Pharmaceuticals (AMRX) Valuation As Analyst Optimism And Revenue Outlook Support Recent Momentum
Amneal Pharmaceuticals (AMRX) is experiencing positive momentum due to strong revenue growth, a positive earnings outlook, and strategic government contracts, with its stock performing well recently. Analysts believe the stock is currently undervalued by 5.3% at US$13.26, with a fair value estimated at US$14.00, driven by assumptions about product launches, cost management, and pipeline execution. The company's recent debt refinancing and anticipated tax benefits are expected to enhance financial flexibility and allow for reinvestment in high-growth areas like biosimilars, potentially boosting future earnings and free cash flow.
Amneal Pharmaceuticals stock hits 52-week high at $13.04 By Investing.com
Amneal Pharmaceuticals stock (AMRX) reached a 52-week high of $13.04, marking a 63.58% increase over the past year and 50.95% in six months, demonstrating strong investor confidence. The company's performance is supported by a solid current ratio of 2.13 and recent FDA approvals for two denosumab biosimilars and an epinephrine injection. Analysts predict profitability this year, although InvestingPro suggests the stock may be slightly overvalued.
Amneal Pharmaceuticals stock hits 52-week high at $13.04 By Investing.com
Amneal Pharmaceuticals Inc. (AMRX) stock reached a new 52-week high of $13.04, reflecting a significant 63.58% rise over the past year and a 50.95% gain in six months. The company's performance is supported by a strong current ratio and investor confidence, despite some InvestingPro analysis suggesting it's slightly overvalued. Recent positive developments include FDA approvals for two denosumab biosimilars and an epinephrine injection, as well as positive interim results from its Parkinson's disease treatment study.
Amneal Pharmaceuticals stock hits 52-week high at $13.04
Amneal Pharmaceuticals Inc. Class A stock recently reached a 52-week high of $13.04, reflecting a significant increase of 63.58% over the past year and 50.95% in the last six months. This performance is attributed to strategic initiatives and favorable market conditions, with the company demonstrating a strong current ratio and a bullish analyst consensus. Recent FDA approvals for biosimilars Boncresa and Oziltus, as well as an epinephrine injection, and positive Phase 4 study results for CREXONT, further highlight Amneal's expanding portfolio and investor confidence despite being considered slightly overvalued.
Amneal Pharmaceuticals stock hits 52-week high at $12.99 By Investing.com
Amneal Pharmaceuticals' stock (AMRX) recently reached a new 52-week high of $12.99, demonstrating significant market performance with a 65.92% increase over the past year. This achievement follows the FDA approval of two denosumab biosimilars and an epinephrine injection, expanding Amneal’s offerings, along with positive interim results from its Parkinson's disease treatment study. Despite being considered slightly overvalued, analysts maintain a "Buy" consensus, with price targets up to $15.
Amneal Pharmaceuticals stock hits 52-week high at $12.99
Amneal Pharmaceuticals Inc Class A stock recently reached a 52-week high of $12.99, demonstrating significant market performance with a 65.92% increase over the past year. This surge is supported by recent FDA approvals for two denosumab biosimilars and an epinephrine injection, alongside positive interim results from its Parkinson's disease study. Despite being considered slightly overvalued by InvestingPro analysis, analysts maintain a "Buy" consensus with price targets up to $15, reflecting confidence in the company's strategic initiatives and growth potential.
Amneal Pharmaceuticals stock hits 52-week high at $12.99 By Investing.com
Amneal Pharmaceuticals Inc. Class A stock recently reached a 52-week high of $12.99, nearly doubling its 52-week low, reflecting strong market performance and investor confidence. The company also announced FDA approvals for two denosumab biosimilars and an epinephrine injection, alongside positive interim results for its Parkinson's disease treatment, CREXONT. Despite a slight overvaluation according to InvestingPro, analysts maintain a "Buy" consensus with price targets up to $15, supported by solid financials and strategic growth initiatives.
Amneal Pharmaceuticals stock hits 52-week high at $12.99 By Investing.com
Amneal Pharmaceuticals stock reached a 52-week high of $12.99, nearly doubling its 52-week low, reflecting strong market performance and investor confidence. The company also announced FDA approvals for two denosumab biosimilars and an epinephrine injection, alongside positive interim results for its Parkinson's disease treatment, CREXONT. Despite concerns about slight overvaluation, analysts maintain a Buy consensus with price targets up to $15.
Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®
Amneal Pharmaceuticals, Inc. announced FDA approval for its denosumab biosimilars Boncresa™ (referencing Prolia®) and Oziltus™ (referencing XGEVA®). This expands Amneal's biosimilars portfolio to five commercial products, strengthening its position in the rapidly growing market for affordable medicines. The partnership with mAbxience underscores a commitment to expanding access to high-quality biologic medicines in the U.S.
